GlassScriptPhysician profile
Matthew W Weber
NPI 1104323567
$1,747.63
in general payments reported to CMS, 2019-2025
12 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $340 · 2023: $1,038 · 2024: $169 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Education: $183 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.26 |
| Education | $182.98 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $124.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $379.04 | 2022-2023 | Onureg, Reblozyl |
| Genzyme Corporation | $251.45 | 2023 | |
| Beigene USA, INC. | $164.42 | 2022-2024 | Brukinsa |
| Foundation Medicine, INC. | $124.33 | 2023 | |
| Exelixis INC. | $124.07 | 2023 | Cabometyx |
| Geron Corporation | $123.12 | 2025 | Rytelo |
| Kite Pharma, INC. | $119.69 | 2022 | |
| Genmab U.S., INC. | $110.99 | 2023 | Epkinly |
| Seagen INC. | $99.99 | 2024 | |
| Karyopharm Therapeutics INC. | $90.17 | 2023 | Xpovio |
| Abbvie INC. | $82.99 | 2023 | Venclexta |
| Beone Medicines USA, INC. | $77.37 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.